SCHEMBL4153796

SCHEMBL4153796

O=Cc1cccc(-c2ccc3[nH]c(=O)c4[nH]cc(CCC(=O)O)c4c3c2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.39
TRIM33 Q9UPN9 1/20 0.39
EGFR P00533 2/20 0.38
PDGFRB P09619 2/20 0.38
FGFR1 P11362 2/20 0.38
KDR P35968 2/20 0.38
GPR17 Q13304 2/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37
GRIN2B Q13224 1/20 0.37
GRIN2C Q14957 1/20 0.37
GRIN3A Q8TCU5 1/20 0.37
PARP1 P09874 1/20 0.36
FFAR1 O14842 1/20 0.36
PTGER1 P34995 1/20 0.35
PTGER4 P35408 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4153837 0.89 GPR17 (0.45) EGFRPDGFRBFGFR1KDRGPR17
SCHEMBL4166164 0.87 GPR17 (0.40) EGFRPDGFRBFGFR1KDRGPR17
SCHEMBL4157563 0.86 HPGD (0.49) EGFRPDGFRBFGFR1KDRGPR17
SCHEMBL4163088 0.85 GRIN2D (0.45) EGFRPDGFRBFGFR1KDRGPR17
SCHEMBL4160171 0.83 MAPT (0.43) EGFRPDGFRBFGFR1KDRGPR17
SCHEMBL4155339 0.83 CAMKK2 (0.40) EGFRPDGFRBFGFR1KDRGPR17
SCHEMBL4162598 0.83 HPGD (0.52) EGFRPDGFRBFGFR1KDRGPR17
SCHEMBL3249890 0.83 TRIM24 (0.45) TRIM24TRIM33HPGDGRIN2DGRIN3B
SCHEMBL4157735 0.82 NR4A2 (0.44) GPR17HPGDCYP2C19
SCHEMBL4165158 0.82 MME (0.42) HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 TRIM24 2253/4885TRIM33 3206/4885EGFR 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.